<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979247</url>
  </required_header>
  <id_info>
    <org_study_id>VOLITION</org_study_id>
    <nct_id>NCT04979247</nct_id>
  </id_info>
  <brief_title>Intravenous Oliceridine and Opioid-related Complications</brief_title>
  <official_title>Intravenous Oliceridine and Opioid-related Complications: VOLITION: A Multicenter Pilot Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will evaluate the side effects of oliceridine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will evaluate the side effects of oliceridine. Limited information suggests&#xD;
      that oliceridine may cause fewer side effects than the standard opioids given post surgery.&#xD;
      Oliceridine is effective for treating acute pain, and is approved by the FDA. Patients will&#xD;
      wear a device that continuously monitors breathing. Data from this monitor will be blinded to&#xD;
      the clinical staff. Primary Aims include: The investigators will evaluate the proportion of&#xD;
      patients having an adjudicated meaningful respiratory compromise with a specified precision&#xD;
      of 0.15 using a 95% confidence interval at 24 hours post first study dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who have respiratory compromise.</measure>
    <time_frame>24 hours post first study dose.</time_frame>
    <description>Respiratory compromise will be defined by a collapsed (one or more) composite of 1) end-tidal carbon dioxide &lt;15mmHg for ≥3 minutes; 2) respiratory rate ≤5 breaths/minute for ≥3 minutes; 3) SpO2 ≤ 85% for ≥3 minutes; 4) Apnea episode lasting &gt;30 seconds; 5)any serious respiratory event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of oxygen saturation &lt; 90%</measure>
    <time_frame>48 hours post first study dose.</time_frame>
    <description>The sum of minutes with SpO2&lt;90% from monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of respiratory rate &lt; 8 breaths/ minute</measure>
    <time_frame>48 hours post first study dose.</time_frame>
    <description>The sum of minutes with respiratory rate &lt; 8 from monitoring data</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Surgery</condition>
  <arm_group>
    <arm_group_label>Oliceridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Oliceridine for pain control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oliceridine</intervention_name>
    <description>Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.</description>
    <arm_group_label>Oliceridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status 1-4&#xD;
&#xD;
          -  Scheduled for major noncardiac surgery expected to last at least 2 hours&#xD;
&#xD;
          -  Expected to remain hospitalized at least two postoperative nights&#xD;
&#xD;
          -  Scheduled for general endotracheal, spinal anesthesia, or the combination&#xD;
&#xD;
          -  Expected to require substantial opioid analgesia, defined as ≥20 mg morphine&#xD;
             equivalents&#xD;
&#xD;
          -  Expected to have patient-controlled intravenous analgesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are demented or otherwise cannot provide valid consent&#xD;
&#xD;
          -  Have contraindications to oliceridine&#xD;
&#xD;
          -  Used legal or illegal opioids chronically, defined as &gt;15 mg morphine equivalents for&#xD;
             &gt;15 days during the month before consenting by history&#xD;
&#xD;
          -  Have language, vision, or hearing impairments that may compromise continuous&#xD;
             ventilation monitoring&#xD;
&#xD;
          -  Have planned epidural anesthesia/analgesia&#xD;
&#xD;
          -  Planned spinal morphine administration&#xD;
&#xD;
          -  Are designated Do Not Resuscitate, hospice, or receiving end of life therapy&#xD;
&#xD;
          -  Are expected to require postoperative mechanical ventilation or ICU admission&#xD;
&#xD;
          -  Are expected to receive intrathecal opioids&#xD;
&#xD;
          -  Are expected to receive gabapentin, pregabalin or other analgesic adjuvants&#xD;
&#xD;
          -  Use oxygen at home&#xD;
&#xD;
          -  Are unwilling or unable to comply fully with study procedures (including not&#xD;
             tolerating the capnography cannula)&#xD;
&#xD;
          -  Are known to be pregnant or breastfeeding&#xD;
&#xD;
          -  Use CPAP at home&#xD;
&#xD;
          -  Have previously participated in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Bapist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish K Khanna, MD</last_name>
      <phone>336-716-4498</phone>
      <email>akhanna@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynnette Harris</last_name>
      <email>lcharris@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ashish K Khanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

